NSE: LALPATHLAB | BSE: 539524

Expensive Performer

Download real time

2862.50 5.50 (0.19%)

46,847 NSE+BSE Volume

NSE 06 Jun, 2025 1:06 PM (IST)

23,980.7

Market Cap

Market Runner Up

0.4

Beta 1Year

Very Low volatility

Dividend

Dr. Lal Pathlabs Ltd. last dividend of ₹6.00 per share was given on 06 Jun 2025 See details

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Search Inside the pdf :

Dr. Lal Pathlabs Ltd.

12 May 2025

2862.50

0.19%

DR. LAL PATH LABS LTD.

Buy: Dr. Lal Pathlabs Ltd.

FundsIndia

Dr. Lal Pathlabs Ltd. is trading below its 200 day SMA of 2944.2

Dr. Lal Pathlabs Ltd.

26 Apr 2025

2862.50

0.19%

Decent quarter, limited headroom for margins expansion

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q4FY25 results were slightly better than our expectation. Outperformance was driven by higher sample volumes (up 9.5% YoY) and realisation improvement.

Dr. Lal Pathlabs Ltd. is trading above its 150 day SMA of 2807.7

Dr. Lal Pathlabs Ltd.

26 Apr 2025

2862.50

0.19%

Steady quarter; encouraging outlook

Buy: Dr. Lal Pathlabs Ltd.

Target

Emkay

DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

14 Feb 2025

2862.50

0.19%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. is trading above its 150 day SMA of 2807.7

Dr. Lal Pathlabs Ltd.

13 Jan 2025

2862.50

0.19%

DR. LAL PATHLABS LTD.

Sell: Dr. Lal Pathlabs Ltd.

Ventura

Elevated Valuations Dampen Strong Fundamentals

Dr. Lal Pathlabs Ltd. is trading below its 200 day SMA of 2944.2

Dr. Lal Pathlabs Ltd.

24 Oct 2024

2862.50

0.19%

Growth moderates; near term green shoots unlikely

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q2FY25 revenue growth of 9.8% YoY was lower than our expectation, though its better EBITDA margin of 30.7% was a surprise.

Dr. Lal Pathlabs Ltd. is trading below its 200 day SMA of 2944.2

Dr. Lal Pathlabs Ltd.

22 Aug 2024

2862.50

0.19%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

08 Aug 2024

2862.50

0.19%

Steady quarter; valuation a bit pricey

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY.

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

19 Jun 2024

2862.50

0.19%

Corner Office view: Spotlight on bundling and Suburban ramp up

Buy: Dr. Lal Pathlabs Ltd.

Emkay

We met DLPL’s MD Dr. Om Manchanda to gauge competitive intensity and its strategy to boost volumes. Meeting KTAs are: 1) DLPL is increasingly witnessing the ‘bundling’ phenomenon as doctors are recommending multiple tests to ascertain accurate prognosis.

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

10 May 2024

2862.50

0.19%

Swasthfit drives the beat

Buy: Dr. Lal Pathlabs Ltd.

Emkay

DLPL posted a robust quarter, with revenue growing 11% YoY on the back of
sample volume increasing 9% YoY and Swasthfit contributing 24% to the
topline.

Dr. Lal Pathlabs Ltd. is trading above its 150 day SMA of 2807.7

Is Dr. Lal Pathlabs Ltd. worth buying?

225 Votes:

Buy 76.0%

Sell 14.67%

Hold 9.33%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf